Search Thermo Fisher Scientific
The SARS-CoV-2 Neutralizing Ab ELISA is a competitive assay that inversely measures neutralizing antibodies against SARS-CoV-2 Spike RBD in human serum or plasma.
原理方法
The Human SARS-CoV-2 Neutralizing Ab ELISA (enzyme-linked immunosorbent assay) is designed to measure the neutralizing portion of anti-SARS-CoV-2 antibodies. A receptor binding domain (RBD) protein is pre-coated in the wells of the supplied microplate. Samples or the positive control are added into the wells and incubated for 30 minutes. Neutralizing antibodies present in a sample that specifically bind to RBD will block the interaction/coverage of RBD with biotinylated ACE2 added for 30 minutes following a wash. Signal from SA-HRP is indirectly proportional to the amount of specific neutralizing antibody present.
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold symptoms to severe effects including death and respiratory distress. The CoV Spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Of note is the Spike protein receptor-binding domain (RBD, S-RBD) in SARS-CoV-2 Spike protein which binds strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibits significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD in comparison. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells.
仅用于科研。不用于诊断过程。未经明确授权不得转售。